SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
CNSP

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$3.56-$0.35 (-9.07%)
 
Market cap
$5.25M
Insider Score
Health Score
Analyst consensus
Listed since
Nov 8, 2019
Market Cap$5.25M-48.0%
Revenue (ttm)$0
Net Income-$15.98M-22.3%
EPS-$18.07+68.9%
Shares Out1.48M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume666
Open$3.68
Previous Close$3.92
Day's Range$3.51 - $3.68
52-Week Range$1.90 - $10.54
Beta1.01
AnalystsBuy
Price Target$0.50(-85.96%)
Earnings DateMar 3, 2027
-10.34% (1D)
No price history available.

About CNSP

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.

Address
2100 West Loop South, Houston, TX, 77027, US
Market Cap
5 million
Employees
8
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$44.01K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Fair
From CNSP’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-9.07%
5 Days
+13.38%
1 Month
-25.05%
6 Months
-34.32%
1 Year
-47.95%

$CNSP stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in CNSP holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by CNSP's directors and management

Net Shares Purchased by Insiders−10k−5k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

CNSP Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New CNSP patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to CNSP from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in CNSP

VXFVanguard Extended Market ETF$78.80K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from CNSP’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
100% of score
4.89
Analyst Ratings
No data yet
—
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
2
Sells
0
Buy Value
$44.01K
Distinct Buyers
2

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.